The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Trump administration is considering a proposal to allow Medicare and Medicaid to cover expensive weight-loss drugs. GLP-1 ...

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...